Trial Profile
A 12 Week, Multi-center, Randomized, Open Label Study, eValuating the Efficacy and Safety of Treatment Regimens That Include ONbrez (Indacaterol) in Patients With Moderate to Severe COPD (MOVE-ON Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Beta 2 adrenergic receptor agonists
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms MOVE-ON
- 29 Jun 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 29 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2011 Planned End Date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.